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Abstract: The transcriptional anti-silencing and DNA-binding protein, VirB, is essential for the
virulence of Shigella species and, yet, sequences required for VirB-DNA binding are poorly understood.
While a 7-8 bp VirB-binding site has been proposed, it was derived from studies at a single
VirB-dependent promoter, icsB. Our previous in vivo studies at a different VirB-dependent promoter,
icsP, found that the proposed VirB-binding site was insufficient for regulation. Instead, the required
site was found to be organized as a near-perfect inverted repeat separated by a single nucleotide
spacer. Thus, the proposed 7-8 bp VirB-binding site needed to be re-evaluated. Here, we engineer and
validate a molecular tool to capture protein-DNA binding interactions in vivo. Our data show that a
sequence organized as a near-perfect inverted repeat is required for VirB-DNA binding interactions
in vivo at both the icsB and icsP promoters. Furthermore, the previously proposed VirB-binding site
and multiple sites found as a result of its description (i.e., sites located at the virB, virF, spa15, and
virA promoters) are not sufficient for VirB to bind in vivo using this tool. The implications of these
findings are discussed.
Keywords: VirB; DNA-binding site; in vivo binding; Shigella; virulence; transcription; anti-silencing
1. Introduction
In Shigella species, expression of a set of virulence genes carried on the large virulence plasmid,
pINV (~220 kb), is controlled by transcriptional silencing and anti-silencing. The DNA-binding protein,
VirB, is central to transcriptional anti-silencing and, therefore, essential for the virulence of these
bacterial human pathogens; without VirB, Shigella flexneri is avirulent [1]. Upon VirB production
at 37 ◦C [2], VirB binds DNA in a sequence-specific manner at VirB-regulated promoters to counter
transcriptional silencing mediated by H-NS, the histone-like nucleoid structuring protein [3–8]. Despite
the importance of VirB-DNA interactions, the DNA recognition sequence for VirB is poorly understood.
Currently, our understanding of DNA sequences required for VirB binding stems from in vitro
analyses of VirB binding at two VirB-dependent promoters: icsB [6,9] and icsP [7,10]. Since VirB
belongs to the ParB protein superfamily [11], the putative VirB-binding site at the icsB promoter
was initially identified due to its similarity to the Box A component of the binding site for P1 ParB
(5′-(A/G)(A/T)G(G)AAAT-3′) [9]. Despite this sequence being organized as an inverted repeat, only
the Box A-like sequence, subsequently renamed Box 2, was shown to be required for VirB-dependent
regulation of the icsB promoter and important for VirB-DNA binding in vitro [6,9]. In contrast, at the
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icsP promoter, which is also organized as a near-perfect inverted repeat 5′-ATTTCAGtATGAAAT-3′,
both boxes (Box 1 and Box 2) are required for VirB-dependent regulation [10].
In vitro investigations of the VirB-binding site [6,7,12] are complicated by the intrinsic property
of VirB to form higher-order oligomers both on [7,12] and off DNA [13], leading to the production of
non-discrete shifts in electrophoretic mobility shift assays [12] and long regions of protection in DNase
I protection assays [7]. As such, if we are to re-analyze DNA sequences required for VirB binding, we
reasoned that in vivo approaches would likely facilitate and lead to a greater understanding of these
key regulatory sequences for Shigella virulence. Thus, we designed a genetic tool to elucidate DNA
sequences required for VirB binding in vivo.
The design of our genetic tool was inspired by the observation that the global transcriptional
regulator of anaerobiosis, FNR, can repress a promoter by simple occlusion of RNA polymerase
when an FNR-binding site is positioned near and within promoter elements [14]. In our genetic tool,
termed the binding tool, protein-DNA binding is captured in vivo by placing a putative DNA binding
sequence immediately upstream of the −35 promoter element of the constitutively active promoter,
Ptac [15], which controls the expression of a lacZ reporter. If the DNA-binding protein of interest binds
the putative recognition site, RNA polymerase will be occluded from the promoter leading to reduced
promoter activity and, consequently, lowered lacZ expression.
In this study, we create and validate the utility of our binding tool using in vivo and in vitro
approaches. We next use the tool and its derivatives to interrogate previously described VirB-binding
sequences and investigate the components necessary and sufficient for VirB to bind to DNA in vivo.
Our findings lead us to challenge the current understanding of a VirB-binding site and allow us to
redefine the sequences necessary and sufficient for VirB-DNA binding.
2. Materials and Methods
2.1. Bacterial Strains, Plasmids, and Media
The bacterial strains and plasmids used in this study are listed in Table 1. The isogenic virB::Tn5 S.
flexneri 2a strain AWY3 [8] was routinely grown at either 25 ◦C or 37 ◦C in LB (Luria–Bertani) broth [16]
with aeration,325 rpm in a LabLine/Barnstead 4000 MaxQ shaker (Thermo Fisher Scientific, Waltham,
MA, USA) or plated on trypticase soy agar (TSA; containing 1.5% w v−1 agar). To ensure plasmid
stability, all pBT series were stocked in Escherichia coli strain JM109(DE3) (Promega, Madison, WI,
USA), which carries lacIq needed to repress Ptac under the standard growth conditions described above.
For selection, antibiotics were added at the following final concentrations: ampicillin (100 µg mL−1),
chloramphenicol (25 µg mL−1), kanamycin (50 µg mL−1), or carbenicillin (100 µg mL−1).
Table 1. Bacterial strains and plasmids used in this study.
Bacterial Strain Description Source
AWY3 Shigella flexneri serotype 2a strain 2457T virB::Tn5; Knr. [8]
JM109(DE3) Escherichia coli strain derived from JM109. Promega
Plasmids Description Source
pACYC177 Low-copy number plasmid vector with a p15A ori; Ampr. [17]
pQF50 Promoterless lacZ transcriptional fusion vector; Cbr. [18]
pQE-60 Vector for C-terminally fused His6-tagged insert; Ampr. Qiagen
pBlueScript II KS(+) Multi-copy cloning vector; Ampr. Stratagene
pHJW14 pBAD18; Cmr. [8]
pHJW16 pHJW14-virB; Cmr. [8]
pHJW43 Source of gfp used to create pBT-empty; Ampr. This work
pAJH03 IPTG inducible plasmid carrying His6-tagged virB. [7]
pNWG08 pBlueScript II KS(+) with NotI BamHI sequence of pBT-PicsP; Ampr. This work
pBT-empty pACYC177 carrying Ptac-lacZ with a unique BglII site immediately adjacent to the −35promoter element. This work
pBT-PicsP pBT-empty with PicsP Box 1 and 2 separated by a single nucleotide spacer5′-ATTTCAGtATGAAAT-3′ [10] This work
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pBT-PicsP-mut1 pBT-empty with mutated PicsP Box 1 This work
pBT-PicsP-mut2 pBT-empty with mutated PicsP Box 2 This work
pBT-PicsP-mutboth pBT-empty with mutated PicsP Box 1 and Box 2 This work
pBT-PicsP-2bp pBT-empty with PicsP Box 1 and 2 with an added 2 bp spacer This work
pBT-PicsB pBT-empty with PicsB Box 1 and 2 separated by a single nucleotide spacer5′-ATTTCATgATGAAAC-3′ [6] This work
pBT-PicsB-mut1 pBT-empty with mutated PicsB Box 1 This work
pBT-PicsB-mut2 pBT-empty with mutated PicsB Box 2 This work
pBT-proposed pBT-empty with proposed 7 bp VirB-binding site [9] flanked by scrambled sequences This work
pBT-Pspa15 pBT-empty with putative VirB-binding site 5′-GAGAAAT-3′ [9] from Pspa15 This work
pBT-PvirA pBT-empty with putative VirB-binding site 5′-GTGGAAAT-3′ [9] from PvirA This work
pBT-PvirB pBT-empty with putative VirB-binding site 5′-ATTGAAAT-3′ [19] from PvirB This work
pBT-PvirF pBT-empty with putative VirB-binding site 5′-GTGCAAAT-3′ [19] from PvirF This work
2.2. Construction of the In Vivo Binding Tool, pBT-Empty
The tac promoter, Ptac [15], was polymerase chain reaction (PCR) amplified from pQE-60 (Qiagen,
Germantown, MD, USA) with primers W344 and W345 (all primers listed in Table 2). The resulting
amplicon was digested with SpeI and SalI, inserted into pBlueScript II KS(+) (Stratagene/Agilent,
Santa Clara, CA, USA), and verified by Sanger sequencing (Genomics Core Facility at the University of
Nevada Las Vegas, Las Vegas, Nevada, USA). Next, the lacZ reporter gene from pQF50 was introduced
downstream of Ptac. To do this, lacZ was PCR amplified from pQF50 [18] using W342 and W343. The
resulting amplicon was digested with BamHI and XhoI, inserted into the plasmid backbone, and the
Lac+ phenotype of cells bearing this construct was confirmed on plates containing X-gal (40 µg mL−1).
To limit large fluctuations in β-galactosidase activities, the Ptac-lacZ was moved into the low-copy
number plasmid, pACYC177 [17]. To do this, Ptac-lacZ was removed from its plasmid backbone by
digest with BsaAI and EcoO109I. The resulting fragment was ligated to pACYC177 that had been
digested with DraIII, treated with T4 polymerase to create blunt ends, and subsequently digested with
EcoO109I. A unique BglII site that would allow the insertion of putative binding sites immediately
adjacent to the −35 element, was created by PCR-based site-directed mutagenesis using mutagenic
oligonucleotides W395 and W396. The resulting amplicon was digested with SpeI and HindIII and used
to replace the existing sequence. To remedy sequencing problems caused by a DNA repeat (generated
during plasmid construction), an internal fragment of gfp was PCR amplified from pHJW43 using
W412 and W413 and used to replace the repeated sequence. The resulting plasmid, pBT-empty, was
confirmed by digest with BsrGI and NgoMIV and further verified by Sanger sequencing. pBT-empty
has two lacO sites (5′-TTGTGAGCGGATAACAA-3′; [20] one overlapping Ptac (−31 to −15) and the
other downstream (+3 to +19)) that were used to repress Ptac activity and prevent lacZ expression
under standard growth conditions; nevertheless, neither of these sites impacted our in vivo binding
assays because S. flexneri strains do not carry lacI.
Table 2. Oligonucleotides used in this study.
Primer1 Sequence (5′ to 3′) Description or Use
W342 ctagaggatccccgggtacccg Amplification of lacZ from pQF50
W343 gcattactcgagttccttacgcgaaagacgggc
W344 ggaaactagtcgattcgtaggccttgctttgtgagcggataac Amplification of Ptac from pQE60
W345 cgcggtcgaccccatatcaccagctcaccg
W395 ctagaactagtcgattcgtagatcttgctttgtgagcgg Mutagenic primers to generate unique BglII site required
for construction of pBT-emptyW396 agctagaagcttctagagatcccc
W412 tgcattgcggccgcttttctgtcagtggagaggg Amplification of ‘gfp required for construction of
pBT-emptyW413 actgcagccggcaagaaggaccatgtgg
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Primer1 Sequence (5′ to 3′) Description or Use
W414 gatctCGGGGATTTCAGTATGAAATGAAGTg Annealed to generate wild-type PicsP Box 1 & 2
W463 gatccACTTCATTTCATACTGAAATCCCCGa
W527 gatctCGGGGATTTCAGTcgacccgGAAGTg Annealed to generate mutated PicsP Box 1
W528 gatccACTTCcgggtcgACTGAAATCCCCGa
W529 gatctCGGGGgcccagcTATGAAATGAAGTg Annealed to generate mutated PicsP Box 2
W530 gatccACTTCATTTCATAgctgggcCCCCGa
W416 gatctCGGGGgcccagcTcgacccgGAACTg Annealed to generate mutated PicsP Box 1 & 2
W464 gatccAGTTCcgggtcgAgctgggcCCCCGa
W587 gatctCGGGGATTTCAGcgTATGAAATGAAGTg Annealed to create insert with 2 bp between PicsP Box 1 & 2
W588 gatccACTTCATTTCATacGCTGAAATCCCCGa
W443 gatctTGCTCGTTTCATCATGAAATCCCACg Annealed to generate wild-type PicsB Box 1 & 2
W444 gatccGTGGGATTTCATGATGAAACGAGCAa
W445 gatctTGCTCagggcagCATGAAATCCCACg Annealed to generate mutated PicsB Box 1
W446 gatccGTGGGATTTCATGctgccctGAGCAa
W474 gatctTGCTCGTTTCATCgctgggcCCCACg Annealed to generate mutated PicsB Box 2
W450 gatccGTGGGgcccagcGATGAAACGAGCAa
W596 gatctagtcagtcaATTTCAGgatcgatgcc Annealed to generate proposed VirB-binding site
W597 gatccCGATCGATCCTGAAATTGACTGACTa
W627 gatctGCTTTGAGAGAATTGAGAAATGCAAg Annealed to generate putative VirB-binding site at Pspa15
W628 gatccTTGCATTTCTCAATTCTCTCAAAGCa
W629 gatctATAATTGTTTTTAGTGGAAATGTATg Annealed to generate putative VirB-binding site at PvirA
W630 gatccATACATTTCCACTAAAAACAATTATa
W631 gatctTTCTCTTTCTCTGATTGAAATGCTGg Annealed to generate putative VirB-binding site at PvirB
W632 gatccCAGCATTTCAATCAGAGAAAGAGAAa
W633 gatctATAGTAACTTTCAGTGCAAATACTTg Annealed to generate putative VirB-binding site at PvirF
W634 gatccAAGTATTTGCACTGAAAGGGACTATa
W119 gccagggttttgggagtcacga Sequencing primer, M13F
W120 gagcggataacaatttcacacagg Sequencing primer, M13R
W482 tgtggtgcaacgggcgctgg Sequencing primer
W483 agaagcctgcgatgtcggtt Sequencing primer
W484 caccgatattatttgcccga Sequencing primer
W485 cctctggatgtcgctccaca Sequencing primer
W486 ggcagcatcaggggaaaacc Sequencing primer
W487 gcacatttccccgaaaagtg Sequencing primer
W488 ggaagacgtacggggtatac Sequencing primer
W489 ccagctcgatgcaaaaatcc Sequencing primer
W490 ccacccagtcccagacgaag Sequencing primer
W491 ccacagcggatggttcggat Sequencing primer
W492 cggtttatgcagcaacgaga Sequencing primer
W541 gcggccgctctagaactagtcg Sequencing primer
The VirB-binding site components, Box 1 and 2, are indicated in bold. DNA sequences native to the icsB, icsP,
spa15, virA, virB, and virF promoters are in uppercase and mutated/random sequences are in lower-case. All
oligonucleotides were ordered from Integrated DNA Technologies1.
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2.3. Construction of the In Vivo Binding Tool Derivatives
To construct the pBT derivatives, oligonucleotides were routinely annealed to create a 25 bp
insert containing sites of interest flanked by native DNA sequences (unless otherwise noted) and
compatible BglII and BamHI cohesive ends. Annealing reactions were done using an equimolar ratio
of oligonucleotides, diluted to a final concentration of 1 pmol µL−1 in a Tris buffer (10 mM Tris, 1 mM
EDTA, 50 mM NaCl (pH 7.5)). Oligonucleotide mixtures were annealed in a PCR machine [95 ◦C
for 5 min, 1 ◦C less min−1 until annealing temperature reached, 30 min at annealing temperature,
1 ◦C less min−1 until 4 ◦C reached]. The 25 bp inserts were then ligated into the BglII site positioned
immediately upstream of the −35 promoter element of Ptac in pBT-empty. The forward orientation of
the 25 bp insert was determined by digest with BglII and BamHI. All of the resulting constructs were
confirmed by Sanger sequencing. To create the pBT derivative pNWG08 (DNase I protection assays),
the Ptac region carrying the VirB-binding site from the icsP promoter [10] was cut from pBT-PicsP with
NotI and BamHI, and ligated to a similarly digested pBlueScript II KS(+).
2.4. Purification of VirB
The VirB-His6 translational fusion protein was produced from pAJH03 and purified by the
Monserate Biotechnology Group (San Diego, CA, USA) as described previously [7]. The His6-tag
did not interfere with VirB expression or activity since His6-tagged VirB restored icsP expression to
wild-type levels in a strain lacking virB in vivo [7].
2.5. DNase I Protection Assays
To identify regions bound by VirB and the RNA polymerase holoenzyme on pBT-icsP promoter
fragments, DNase I protection assays were completed using [γ−32P]-ATP 5′ end labeled NotI BamHI
fragments (159 bp). For each reaction, a final concentration of 6.4 nM of template DNA, sourced
from pNWG08, was used with purified His6-tagged VirB (0, 30.7, 61.4, 122.8 or 307 nM) or E. coli
RNA polymerase holoenzyme (0.0125, 0.025, 0.05, or 0.1 units µL−1; Product No. 78040Y supplied by
Affymetrix, Inc/Thermo Fisher Scientific, Waltham, MA, USA). Samples were incubated at 37 ◦C for
30 min in a 20 µL reaction containing 50 mM Tris-HCl (pH 8.0), 20 mM KCl, 10% glycerol, 100 µg mL−1
bovine serum albumin (BSA), and 25 µg mL−1 poly (dI-dC). DNase I digestion was carried out as
described previously [7]. Samples were treated with 3µl of 1:100 diluted DNase I (New England
Biolabs, Ipswich, MA, USA) for 30 s followed by phenol-chloroform DNA extraction and ethanol
precipitation. DNA was resuspended in a gel loading buffer (40% deionized formamide, 5 M urea,
5 mM NaOH, 1 mM EDTA, 0.025% bromophenol blue, and 0.025% xylene cyanol) and analyzed by 6%
denaturing PAGE by comparing with a DNA sequence ladder generated using a Maxam and Gilbert
A+G reaction [21]. Radiolabeled DNA was detected using a Typhoon 9410 (Amersham/GE, Chicago,
IL, USA) variable mode imager and ImageQuant 5.2.
2.6. β-Galactosidase Assays
To determine sequences required or sufficient for VirB binding, plasmids in the pBT series
were introduced into the S. flexneri virB mutant strain AWY3 carrying the L-arabinose inducible
pBAD-virB (pHJW16) or pBAD-empty control (pHJW14) by electroporation. The use of this inducible
system allowed optimal assay conditions to be found given the low, but multi-copy nature of the
pBT series. Promoter activities were determined by measuring β-galactosidase activity (protocol
adapted from [22] and is described in [8]). Cultures were grown overnight (16 h) at 25 ◦C in LB
broth containing 0.2% D-glucose, ampicillin (100 µg mL−1), and chloramphenicol (25 µg mL−1).
Overnight cultures were then diluted 1:100 to grow for 8 h at 37 ◦C with aeration (325 rpm
in a LabLine/Barnstead 4000 MaxQ shaker) in LB broth containing 0.2% L-arabinose, ampicillin
(100 µg mL−1), and chloramphenicol (25 µg mL−1) prior to cell lysis. Three separate β-galactosidase
assay trials, each from three independent transformations, were used to generate all presented data.
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Only the representative data is shown. The equality of variance for each dataset was calculated using
F-tests and standard error p > 0.001 was calculated using an unpaired two-tailed Student’s t-test that
assumed either equal or unequal variance.
3. Results
3.1. Experimental Validation of the In Vivo Binding Tool
The starting point for this work was the newly constructed low-copy reporter plasmid, pBT-empty,
which contains Ptac [15] transcriptionally fused to lacZ (Figure 1Ai). To test DNA sequences required
for VirB binding in vivo, putative cognate DNA sequences were inserted into a unique BglII restriction
site positioned immediately upstream and adjacent to the −35 promoter element of Ptac in pBT-empty.
We hypothesized that if VirB binds to the inserted sequences, RNA polymerase would be sterically
hindered from engaging promoter elements (Figure 1Aii) required for transcription initiation, which
would result in low Ptac activity and low lacZ expression [14]. However, if no sequences were inserted
or the putative binding site was not sufficient for protein-DNA binding, RNA polymerase would not
be occluded from promoter elements and lacZ would be expressed.
To test the hypothesized function of our in vivo binding tool, we measured the Ptac activities of
pBT-empty and pBT-PicsP, which contains the VirB-binding site from the icsP promoter (Table 1), in the
presence and absence of VirB (Figure 1B). To do this, pBT-empty or pBT-PicsP was introduced into S.
flexneri virB mutant cells along with an L-arabinose inducible pBAD expression vector carrying either
virB (pBAD-virB) or no gene (pBAD-empty). The Ptac activities were measured using β-galactosidase
assays. Our data show that under inducing conditions, Ptac activity only decreases significantly
when both VirB and the icsP VirB-binding site (pBT-PicsP) are present (Figure 1B). Additionally, in the
absence of this VirB-binding site (pBT-empty) and regardless of whether VirB is present, Ptac activity is
not significantly altered. Thus, these data support the proposed function of our binding tool, namely,
that when VirB binds to its cognate DNA sequence in pBT-icsP (as described previously; [7]) promoter
occlusion occurs, resulting in lower β-galactosidase activities. Similar results were obtained when
these pBT-derivatives were assayed in wild-type S. flexneri and an isogenic virB mutant derivative;
however, due to the low but multi-copy nature of our binding tool reporter, exogenous expression of
virB generated higher fold-changes (4-8 fold versus a 3 fold-change) in our assays.
To further validate our tool, we next chose to examine if the VirB and RNA polymerase footprints
at the Ptac region for pBT-PicsP overlap. To do this, regions of DNA bound by VirB and the RNA
polymerase holoenzyme were identified using DNase I protection assays on a radiolabeled DNA
fragment obtained from pBT-PicsP. DNA regions protected by VirB were observed with increasing
VirB concentrations as compared to the no VirB control (Figure 1C). High affinity VirB-DNA binding
(black line; Figure 1C) was observed between −46 to −69 relative to the tac transcription start site
(+1), which correlates well with the inserted VirB-binding site positioned at −46 to −60 relative to
the +1. Strikingly, with just a 2.5-fold increase in VirB (122.8 to 307 nM), an extended footprint was
observed (dotted line; Figure 1C), once again revealing that with concentrations modestly higher
than those needed to occupy the VirB binding site, VirB is able to spread along DNA sequences
from its cognate site [7]. When investigating the DNase I protection exhibited by RNA polymerase
holoenzyme, DNA sequences between +22 to −37 (black line; Figure 1C) were found to be strongly
protected at all concentrations used. Notably, however, even with the lowest concentration used,
partial protection of sequences located between −55 to −71 (dotted line; Figure 1C), a region that
overlaps the VirB-protected region (−69 to −46), was observed. This demonstrates that VirB and RNA
polymerase bind to overlapping DNA sequences in this semi-synthetic promoter. Altogether, these
data support our conceptual model of the binding tool; that VirB binds to its cognate DNA sequence in
pBT-icsP (as described previously; [7]) and occludes RNA polymerase from initiating transcription
at Ptac, and so we conclude that our binding tool can, indeed, be used to capture specific VirB-DNA
binding interactions in vivo.
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Figure 1. Schematic and validation of the in vivo binding tools pBT-empty and its derivative pBT-PicsP.
(A) Schematic of (i) pBT-empty and (ii) pBT-PicsP, showing the hypothesized steric hindrance of
RNA polymerase (RNAP) when VirB engages its binding site. (B) Ptac promoter activity associated
with pBT-empty or pBT-PicsP in the presence (pBAD-virB) or absence (pBAD-empty) of VirB in a S.
flexneri virB mutant, as determined by β-galactosidase assays. Assays were conducted in triplicate,
and representative data of three independent trials are shown. A Student’s t-test was used to measure
statistical significance, * p < 0.001. (C) DNase I protection assays showing that VirB and RNAP occupy
overlapping regions in pBT-PicsP. Lanes are organized (left to right): A+G sequencing ladder [21]
and template DNA (6.4 nM) incubated with zero (-) or increasing final concentrations of His6-tagged
VirB (30.7, 61.4, 122.8, or 307 nM) or RNA polymerase (0.0125, 0.025, 0.05, or 0.1 units µL−1). Black
lines represent regions protected from DNase I at low concentrations (i.e., high affinity protein-DNA
binding); whereas dotted lines represent regions protected from DNase I at high concentrations (i.e.,
low affinity protein-DNA binding). Bold and uppercase text are the VirB-binding site (inverted repeat),
promoter elements (−35 and −10) and transcription start site (+1).
3.2. VirB Binds the Near-Perfect Inverted Repeats from the icsP and icsB Promoters In Vivo
Having validated the function of our in vivo binding tool, we next addressed the apparent
discrepancy between the VirB-binding sites located at the icsP [7,10] and icsB promoters [6,9] (i.e., that
VirB-dependent regulation requires only Box 2 at the icsB promoter, whereas the entire inverted repeat
(Box 1 and Box 2) is required at the icsP promoter). To do this, we opted to test the role of both boxes
from either the icsP or icsB promoters for VirB binding in vivo. Sequences of interest (i.e., native Box
1, Box 2, or the inverted repeats; Figure 2A,B) were inserted into pBT-empty and promoter activities
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of the resulting constructs were measured in a S. flexneri virB mutant harboring either pBAD-virB or
pBAD-empty using β-galactosidase assays.
Again, our results show that Ptac activity from pBT-PicsP, containing the near perfect inverted
repeat, was significantly decreased in the presence of VirB as compared to its absence, suggesting that
VirB is able to bind and occlude RNA polymerase from Ptac under these conditions (Figures 2C and 1B).
However, when Box 1, Box 2, or both are mutated (Figure 2A), no significant change in promoter
activity was observed in the presence or absence of VirB (Figure 2C). In addition, when two additional
nucleotides were inserted between the two boxes that comprise the inverted repeat (pBT-PicsP-2bp), a
statistically significant but modest decrease in Ptac activity was observed in the presence of VirB as
compared to its absence (Figure 2C). Thus, we conclude that the presence of both boxes is not sufficient
for VirB binding in vivo if the spacing is not optimal.
Figure 2. Investigation of sequences required and sufficient for VirB-binding in vivo from the icsP and
icsB promoters. (A,B) DNA sequences inserted into pBT-empty. Uppercase nucleotides refer to native
sequences; lowercase nucleotides refer to mutated sequences. Box 1 and Box 2 are in bold. (C,D) Ptac
activities were measured in the presence (pBAD-virB) or absence (pBAD-empty) of VirB in a S. flexneri
virB mutant using β-galactosidase assays. Data is representative of three independent trials and *
denotes a statistical significance of p < 0.001.
For sequences taken from the icsB promoter (Figure 2B,D), our results showed that the Ptac
activity of pBT-PicsB, containing Box 1 and Box 2 from the icsB promoter, was significantly lower
in the presence of VirB as compared to its absence (Figure 2D). These results were expected since
the characterized VirB-binding site for the icsB promoter, Box 2 [6,9], was present. However, when
Box 2 alone was present (i.e., Box 1 mutated; pBT-PicsB-mut1), surprisingly a decrease in Ptac activity
was not observed in the presence of VirB (Figure 2D). Similarly, when Box 1 alone was present (i.e.,
Box 2 mutated; pBT-PicsB-mut2) promoter activity was not altered in the presence or absence of VirB
(Figure 2D). Thus, contrary to previous findings that report that Box 2 alone is necessary and sufficient
for VirB binding at the icsB promoter, our results show that Box 1 and Box 2 are both required.
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3.3. Re-Examination of VirB-Binding Sites Described in the Literature Using our In Vivo Binding Tool
The proposed VirB-binding site 5′-(A/G)(A/T)G(G)AAAT-3′ was developed during the
investigation of VirB-dependent regulation of the icsB promoter [9] and subsequently used to search
for putative binding sites within the VirB-dependent promoters of virA, spa15, virF, and virB [9,19].
Since our in vivo experiments (Figure 2) demonstrate that VirB only binds to this sequence when it is
organized as an inverted repeat, we hypothesized that the currently proposed 7-8 bp VirB-binding
site [9] and subsequent sites that were identified based on this sequence [9,19] would not be sufficient
for VirB-DNA binding in vivo. To test this, annealed oligonucleotides carrying sequences of interest
(Figure 3A) were inserted in the BglII restriction site in pBT-empty. The plasmid constructs were then
introduced into a S. flexneri virB mutant, along with either pBAD-virB or pBAD-empty. VirB binding
was captured in vivo by measuring Ptac activity using β-galactosidase assays.
Figure 3. Re-examination of VirB-binding sites described in the literature using our in vivo binding tool.
(A) DNA sequences inserted into pBT-empty. Putative VirB-binding sites described in the literature are
in bold. Uppercase nucleotides refer to native sequences or the proposed site; lowercase nucleotides
refer to scrambled sequences. (B) Ptac activities were measured in the presence (pBAD-virB) or absence
(pBAD-empty) of VirB in a S. flexneri virB mutant using β-galactosidase assays. Data is representative
of three independent trials and * denotes a statistical significance of p < 0.001.
Our data show that in the presence of VirB, the currently proposed VirB-binding site
(pBT-proposed) and putative sites established from it (i.e., sites from the spa15 (pBT-Pspa15),
virA (pBT-PvirA), virB (pBT-PvirB), and virF (pBT-PvirF) promoters [9,19]) did not significantly
decrease Ptac activity in the presence of VirB (Figure 3B), suggesting that none of these sites
are sufficient for VirB binding in vivo, at least within the context of the binding tool. This is
in stark contrast to the wild-type sequences taken from the icsP and icsB promoter, which were
again found to be required for VirB binding in vivo (Figure 3B). Cumulatively, these results
strongly suggest that VirB-DNA binding requires a near-perfect inverted repeat with the sequence
5′-ATTT(C)C(A/T)(C/T)n(A/G)(A/T)G(G)AAAT-3′.
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4. Discussion
In this work we describe and validate a new genetic tool that can be used to examine protein
binding to specific DNA sequences in vivo. Simply by placing a putative binding site immediately
adjacent to the −35 element of a constitutively active promoter, we were able to indirectly observe
protein binding through promoter occlusion using β-galactosidase assays. We anticipate that this tool
may prove helpful to those investigating DNA-protein interactions, especially when the DNA-binding
protein is known to be recalcitrant in vitro.
Using our newly described tool, we examined DNA sequences previously reported to be required
for the binding of a key transcriptional regulator of Shigella virulence genes, VirB. Strikingly, our data
show that only sites organized as near perfect inverted repeats separated by a single nucleotide are
required for VirB binding in vivo. This contrasts with reports in the literature that indicate that a single
7-8 bp site, constituting the currently proposed VirB-binding site 5′-(A/G)(A/T)G(G)AAAT-3′ [9], is
sufficient for VirB binding. Our findings demonstrate that neither this proposed 7-8 bp site nor many
of the subsequently identified putative sites (i.e., those described at the VirB-dependent virB, virF, virA,
and spa15 promoters; [9,19]) are sufficient for DNA binding in vivo. As such, this study challenges our
current understanding of VirB-binding sequences and raises questions about these discrepant findings.
Many of the experiments that led to the description of the currently proposed VirB-binding
site 5′-(A/G)(A/T)G(G)AAAT-3′ were different from those used in this work. For instance,
these foundational experiments were done at ambient temperatures rather than 37 ◦C, measured
VirB-dependent regulation and not binding per se, and, perhaps more importantly, relied upon
the exogenous expression of virB from an inducible plasmid well into stationary phase [6,9,19].
Although follow-up in vitro experiments were used to support the finding that VirB-dependent
regulation requires a 7-8 bp VirB-binding site, we now know that these experiments have limited
use when determining DNA sequence requirements for VirB binding because VirB is a promiscuous
DNA-binding protein. Indeed, even in the aforementioned assays, VirB engaged DNA fragments
bearing mutated VirB-binding sites, although higher concentrations of VirB were required to occupy
mutated sites than wild-type sites [6].
In support of our finding that the bona fide VirB-binding site comprises an inverted repeat
separated by a single nucleotide, in silico analysis of the large virulence plasmid of S. flexneri 2a,
pCP301 [23] for the proposed 7-8 bp VirB-binding site, identified 258 perfect matches and 4,332
matches with a single nucleotide mismatch. Similar results were obtained when the large virulence
plasmid of S. flexneri 5a, pWR100 [24] was analyzed. In contrast, only eight sites were found when we
searched for our proposed VirB-binding site either as a perfect match or with a single mismatch. This
is a more biologically relevant number given 10–15 promoters, which are estimated to control about 50
genes, are estimated to be regulated by VirB [24]. Intriguingly, however, these eight sites mapped to
the intragenic regions of ipaH7.8 and spa47, the intergenic regions of ospD1 and icsB (and hence ipgD),
both the intergenic and intragenic of icsP, upstream of a putative transposase, and in the parS locus of
pINV. As such, these sites do not perfectly map to the promoters of VirB-regulated genes identified by
high-quality macroarray analysis [24]. Work is in progress to address these discrepant findings.
While we favor the idea that genuine VirB-binding sites are organized as an inverted repeat, it
is possible that in some cases multiple 7-8 bp sites arranged in a modular format may support VirB
binding. This kind of arrangement may explain why the 7-8 bp sites identified at the virB, virF, virA,
and spa15 promoters [9,19] were found to be insufficient for VirB binding when taken out of their
natural context and inserted into our binding tool. If modular VirB-binding sites exist, however, then
our work highlights that the correct spacing or phasing of these sites is likely to be important for VirB
binding, because a 2 bp insertion between the two 7-8 bp sites that comprise the icsP inverted repeat
significantly lowered VirB binding (Figure 2C). These ideas will be tested in future work.
In conclusion, this study provides new insight into the DNA-binding requirements of a key
regulator of virulence gene expression in Shigella species. Based on our findings, we suggest
that VirB-binding sites are primarily organized as inverted repeats comprised of the half-sites
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5′-(A/G)(A/T)GAAAT-3′ that are separated by a single nucleotide spacer. Examples of these inverted
repeats are found at the icsP promoter (as reported previously; [7,10,25]) but also at the icsB promoter.
While other examples of this site on the Shigella flexneri genome exist, their role in VirB binding and
VirB-dependent regulation of proximal genes is currently being investigated. In closing, if we are to
more thoroughly understand where VirB binds to DNA, the arrangement of these sites with respect to
one another, and how these VirB-DNA interactions ultimately allow transcriptional anti-silencing of
Shigella virulence genes, genome-wide studies that capture all VirB-DNA interactions will be required.
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